The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST) : study protocol for a randomized controlled trial. / Winther, Kristian Hillert; Watt, Torquil; Bjørner, Jakob Bue; Cramon, Per; Feldt-Rasmussen, Ulla; Gluud, Christian; Gram, Jeppe; Grønvold, Mogens; Hegedüs, Laszlo; Knudsen, Nils; Rasmussen, Ase Krogh; Bonnema, Steen Joop.

I: Trials, Bind 15, 115, 09.04.2014, s. 1-11.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Winther, KH, Watt, T, Bjørner, JB, Cramon, P, Feldt-Rasmussen, U, Gluud, C, Gram, J, Grønvold, M, Hegedüs, L, Knudsen, N, Rasmussen, AK & Bonnema, SJ 2014, 'The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial', Trials, bind 15, 115, s. 1-11. https://doi.org/10.1186/1745-6215-15-115

APA

Winther, K. H., Watt, T., Bjørner, J. B., Cramon, P., Feldt-Rasmussen, U., Gluud, C., ... Bonnema, S. J. (2014). The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial. Trials, 15, 1-11. [115]. https://doi.org/10.1186/1745-6215-15-115

Vancouver

Winther KH, Watt T, Bjørner JB, Cramon P, Feldt-Rasmussen U, Gluud C o.a. The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial. Trials. 2014 apr 9;15:1-11. 115. https://doi.org/10.1186/1745-6215-15-115

Author

Winther, Kristian Hillert ; Watt, Torquil ; Bjørner, Jakob Bue ; Cramon, Per ; Feldt-Rasmussen, Ulla ; Gluud, Christian ; Gram, Jeppe ; Grønvold, Mogens ; Hegedüs, Laszlo ; Knudsen, Nils ; Rasmussen, Ase Krogh ; Bonnema, Steen Joop. / The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST) : study protocol for a randomized controlled trial. I: Trials. 2014 ; Bind 15. s. 1-11.

Bibtex

@article{8f0798bc324b429891b6cd02556a2c1c,
title = "The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST): study protocol for a randomized controlled trial",
abstract = "Patients with chronic autoimmune thyroiditis have impaired health-related quality of life. The thyroid gland has a high selenium concentration, and specific selenoprotein enzyme families are crucial to immune function, and catalyze thyroid hormone metabolism and redox processes in thyroid cells. Previous randomized controlled trials have found that selenium supplementation decreases thyroid-disease-specific antibody levels. We hypothesize that selenium might be beneficial in the treatment of chronic autoimmune thyroiditis.Methods/design: The CATALYST trial is an investigator-initiated randomized, blinded, multicentre clinical trial of selenium supplementation versus placebo in patients with chronic autoimmune thyroiditis. Inclusion criteria: age >=18 years; serum thyroid peroxidase antibody level >=100 IU/ml within the previous 12 months; treatment with levothyroxine and written informed consent. Exclusion criteria: previous diagnosis of toxic nodular goitre, Graves' hyperthyroidism, postpartum thyroiditis, Graves' orbitopathy; previous antithyroid drug treatment, radioiodine therapy or thyroid surgery; immune-modulatory or other medication affecting thyroid function; pregnancy, planned pregnancy or breastfeeding; allergy towards any intervention or placebo component; intake of selenium supplementation >55 mug/day; inability to read or understand Danish or lack of informed consent. The trial will include 2 x 236 participants. The experimental intervention and control groups will receive 200 mug selenium-enriched yeast or matching placebo tablets daily for 12 months. The experimental supplement will be SelenoPrecise(R). The primary outcome is thyroid-related quality of life assessed by the Thyroid Patient-Reported Outcome (ThyPRO) questionnaire. Secondary outcomes include serum thyroid peroxidase antibody concentration; serum triiodothyronine/thyroxine ratio; levothyroxine dosage; adverse reactions and serious adverse effects and events.",
author = "Winther, {Kristian Hillert} and Torquil Watt and Bj{\o}rner, {Jakob Bue} and Per Cramon and Ulla Feldt-Rasmussen and Christian Gluud and Jeppe Gram and Mogens Gr{\o}nvold and Laszlo Heged{\"u}s and Nils Knudsen and Rasmussen, {Ase Krogh} and Bonnema, {Steen Joop}",
year = "2014",
month = "4",
day = "9",
doi = "10.1186/1745-6215-15-115",
language = "English",
volume = "15",
pages = "1--11",
journal = "Trials",
issn = "1745-6215",
publisher = "BioMed Central Ltd.",

}

RIS

TY - JOUR

T1 - The chronic autoimmune thyroiditis quality of life selenium trial (CATALYST)

T2 - study protocol for a randomized controlled trial

AU - Winther, Kristian Hillert

AU - Watt, Torquil

AU - Bjørner, Jakob Bue

AU - Cramon, Per

AU - Feldt-Rasmussen, Ulla

AU - Gluud, Christian

AU - Gram, Jeppe

AU - Grønvold, Mogens

AU - Hegedüs, Laszlo

AU - Knudsen, Nils

AU - Rasmussen, Ase Krogh

AU - Bonnema, Steen Joop

PY - 2014/4/9

Y1 - 2014/4/9

N2 - Patients with chronic autoimmune thyroiditis have impaired health-related quality of life. The thyroid gland has a high selenium concentration, and specific selenoprotein enzyme families are crucial to immune function, and catalyze thyroid hormone metabolism and redox processes in thyroid cells. Previous randomized controlled trials have found that selenium supplementation decreases thyroid-disease-specific antibody levels. We hypothesize that selenium might be beneficial in the treatment of chronic autoimmune thyroiditis.Methods/design: The CATALYST trial is an investigator-initiated randomized, blinded, multicentre clinical trial of selenium supplementation versus placebo in patients with chronic autoimmune thyroiditis. Inclusion criteria: age >=18 years; serum thyroid peroxidase antibody level >=100 IU/ml within the previous 12 months; treatment with levothyroxine and written informed consent. Exclusion criteria: previous diagnosis of toxic nodular goitre, Graves' hyperthyroidism, postpartum thyroiditis, Graves' orbitopathy; previous antithyroid drug treatment, radioiodine therapy or thyroid surgery; immune-modulatory or other medication affecting thyroid function; pregnancy, planned pregnancy or breastfeeding; allergy towards any intervention or placebo component; intake of selenium supplementation >55 mug/day; inability to read or understand Danish or lack of informed consent. The trial will include 2 x 236 participants. The experimental intervention and control groups will receive 200 mug selenium-enriched yeast or matching placebo tablets daily for 12 months. The experimental supplement will be SelenoPrecise(R). The primary outcome is thyroid-related quality of life assessed by the Thyroid Patient-Reported Outcome (ThyPRO) questionnaire. Secondary outcomes include serum thyroid peroxidase antibody concentration; serum triiodothyronine/thyroxine ratio; levothyroxine dosage; adverse reactions and serious adverse effects and events.

AB - Patients with chronic autoimmune thyroiditis have impaired health-related quality of life. The thyroid gland has a high selenium concentration, and specific selenoprotein enzyme families are crucial to immune function, and catalyze thyroid hormone metabolism and redox processes in thyroid cells. Previous randomized controlled trials have found that selenium supplementation decreases thyroid-disease-specific antibody levels. We hypothesize that selenium might be beneficial in the treatment of chronic autoimmune thyroiditis.Methods/design: The CATALYST trial is an investigator-initiated randomized, blinded, multicentre clinical trial of selenium supplementation versus placebo in patients with chronic autoimmune thyroiditis. Inclusion criteria: age >=18 years; serum thyroid peroxidase antibody level >=100 IU/ml within the previous 12 months; treatment with levothyroxine and written informed consent. Exclusion criteria: previous diagnosis of toxic nodular goitre, Graves' hyperthyroidism, postpartum thyroiditis, Graves' orbitopathy; previous antithyroid drug treatment, radioiodine therapy or thyroid surgery; immune-modulatory or other medication affecting thyroid function; pregnancy, planned pregnancy or breastfeeding; allergy towards any intervention or placebo component; intake of selenium supplementation >55 mug/day; inability to read or understand Danish or lack of informed consent. The trial will include 2 x 236 participants. The experimental intervention and control groups will receive 200 mug selenium-enriched yeast or matching placebo tablets daily for 12 months. The experimental supplement will be SelenoPrecise(R). The primary outcome is thyroid-related quality of life assessed by the Thyroid Patient-Reported Outcome (ThyPRO) questionnaire. Secondary outcomes include serum thyroid peroxidase antibody concentration; serum triiodothyronine/thyroxine ratio; levothyroxine dosage; adverse reactions and serious adverse effects and events.

U2 - 10.1186/1745-6215-15-115

DO - 10.1186/1745-6215-15-115

M3 - Journal article

C2 - 24716668

VL - 15

SP - 1

EP - 11

JO - Trials

JF - Trials

SN - 1745-6215

M1 - 115

ER -

ID: 107782041